Nanoparticle Formulation of Sitagliptin Phosphate: A Novel Therapeutic Option for Diabetes Mellitus

The present study was to formulate sitagliptin phosphate nanoparticles by using enteric coated polymers so that the drug is to be released in the small intestine for absorption, bypass the stomach, therefore to reduce side effects which results in improved better patient compliance. * The results of FT-IR study showed that there is no interaction between the drug and the polymers. * The sitagliptin phosphate nanoparticles were prepared by Double Emulsion Solvent Evaporation (DESE) method. * The percentage yields, encapsulation efficiency and drug loading of all formulations were calculated. * Invitro study showed that burst release of the drug was occurred in acid buffer followed by sustained release of drug for 12 hrs. * The burst effect of the best formulations were decreased due to the polymer concentration compared to the other formulations. The best formulations were selected based on the encapsulation efficiency and invitro drug release study. * F6 and F12 were showed the high encapsulation efficiency compared to the other formulations but drug loading was decreased due to the increase in the polymer concentration. * The particle size, zeta potential, polydispersity index for the best formulations were evaluated. * Zeta potential indicated that the nanoparticles have good stability. Polydispersity index showed that the nanoparticles size distribution have high homogenicity. * The best formulations were fitted into Zero Order kinetic model and it followed Non Fickian Diffusion kinetics. Hence it was concluded that the sitagliptin nanoparticles were prepared successfully by the DESE method. From the results, it was observed that the drug polymer concentration influences the encapsulation efficiency and invitro drug release study. The nanoparticles showed that the burst release of drug on acid buffer itself and followed by the sustained release of the drug for 12hrs. Therefore, it could be a novel therapeutic option for the treatment of type II diabetes mellitus